down arrow

BioCardia, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09060U5074
USD
1.47
0.1 (7.3%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.401.49

52 Week

1.003.20
Valuation
Technical
Day's Volume

CASH

108.15 k

Shareholding (Mar 2025)

FII

0.25%

Held by 5 FIIs

DII

97.94%

Held by 2 DIIs

Promoter

0.00%

How big is BioCardia, Inc.?

22-Jun-2025

As of Jun 18, BioCardia, Inc. has a market capitalization of 10.93 million, with net sales of 0.00 million and a net profit of -8.40 million over the last four quarters. The company reported shareholder's funds of 0.84 million and total assets of 3.72 million as of Dec 24.

Market Cap: As of Jun 18, BioCardia, Inc. has a market capitalization of 10.93 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, BioCardia, Inc. reported net sales of 0.00 million and a net profit of -8.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 0.84 million and total assets of 3.72 million.

Read More

What does BioCardia, Inc. do?

22-Jun-2025

BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics for cardiovascular diseases, with a market cap of $10.93 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and has a debt equity ratio of 0.36.

Overview: <BR>BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10.93 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.36 <BR>Return on Equity: 552.04% <BR>Price to Book: -7.19<BR><BR>Contact Details: <BR>Address: 125 Shoreway Rd Ste B, SAN CARLOS CA: 94070-2718 <BR>Tel: 1 650 2260120 <BR>Website: http://www.biocardia.com/

Read More

Who are in the management team of BioCardia, Inc.?

22-Jun-2025

As of March 2022, the management team of BioCardia, Inc. includes Dr. Simon Stertzer (Independent Chairman), Dr. Peter Altman (CEO), Dr. Krisztina Zsebo, and several independent directors: Jim Allen, Andrew Blank, Fernando Fernandez, and Richard Krasno. They oversee the company's strategic direction and operations.

As of March 2022, the management team of BioCardia, Inc. includes the following individuals:<BR><BR>- Dr. Simon Stertzer, Independent Chairman of the Board<BR>- Dr. Peter Altman, President, Chief Executive Officer, and Director<BR>- Dr. Krisztina Zsebo, Director<BR>- Mr. Jim Allen, Independent Director<BR>- Mr. Andrew Blank, Independent Director<BR>- Mr. Fernando Fernandez, Independent Director<BR>- Dr. Richard Krasno, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is BioCardia, Inc. overvalued or undervalued?

25-Jun-2025

As of August 9, 2023, BioCardia, Inc. is considered overvalued and has moved to a "does not qualify" valuation grade due to negative financial ratios and poor stock performance, with a year-to-date return of -7.34% compared to the S&P 500's 2.44%.

As of 9 August 2023, BioCardia, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, especially given its negative financial ratios such as a Price to Book Value of -7.39 and an EV to EBITDA of -1.33. These figures suggest that the company's market valuation does not align with its underlying financial performance.<BR><BR>In comparison to its peers, BioCardia's EV to EBIT ratio of -1.26 is slightly better than Frequency Therapeutics, Inc. at -1.3504, but worse than Landos Biopharma, Inc. at -2.9258. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -7.34%, significantly lagging behind the S&P 500's 2.44% return. Overall, the combination of negative ratios and poor stock performance reinforces the conclusion that BioCardia, Inc. is overvalued in its current state.

Read More

Is BioCardia, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, BioCardia, Inc. shows a mildly bearish trend with mixed technical indicators, including bearish weekly MACD and moving averages, despite a mildly bullish monthly MACD.

As of 12 September 2025, the technical trend for BioCardia, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance, indicating mixed signals across time frames. The Bollinger Bands and Dow Theory both reflect a bearish outlook on a weekly and monthly basis. Daily moving averages are also bearish, further supporting the negative sentiment. The KST is bearish weekly but mildly bullish monthly, adding to the complexity of the analysis. Overall, the indicators suggest a mildly bearish stance, with the stock underperforming compared to the S&P 500, although specific return data is not available for comparison.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.30

stock-summary
Return on Equity

466.28%

stock-summary
Price to Book

-6.43

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.94%
0%
-27.94%
6 Months
-32.57%
0%
-32.57%
1 Year
-32.88%
0%
-32.88%
2 Years
-85.42%
0%
-85.42%
3 Years
-94.51%
0%
-94.51%
4 Years
-94.79%
0%
-94.79%
5 Years
-96.16%
0%
-96.16%

BioCardia, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is BioCardia, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for BioCardia, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance, indicating mixed signals across time frames. The Bollinger Bands and Dow Theory both reflect a bearish outlook on a weekly and monthly basis. Daily moving averages are also bearish, further supporting the negative sentiment. The KST is bearish weekly but mildly bullish monthly, adding to the complexity of the analysis. Overall, the indicators suggest a mildly bearish stance, with the stock underperforming compared to the S&P 500, although specific return data is not available for comparison....

Read More
BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.00

BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.00

BioCardia, Inc. has reached a new 52-week low of USD 1.00, reflecting its performance in a challenging market. With a market cap of USD 12 million, the company has a low debt-to-equity ratio of 0.30 and a high return on equity of 466.28%, despite being loss-making.

Read More
BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.53

BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.53

BioCardia, Inc. has reached a new 52-week low of USD 1.53, contrasting with its high of USD 3.25. With a market cap of USD 12 million, the company shows a low debt-to-equity ratio of 0.30 and a high return on equity of 466.28%, despite being unprofitable.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-11.92%
EBIT Growth (5y)
7.08%
EBIT to Interest (avg)
-11.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.36
Sales to Capital Employed (avg)
-0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.41%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-7.39
EV to EBIT
-1.26
EV to EBITDA
-1.33
EV to Capital Employed
-5.16
EV to Sales
10.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.81%)

Foreign Institutions

Held by 5 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 25.93% vs -17.39% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.60",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-2.70",
          "chgp": "25.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -80.00% vs -64.29% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 31.90% vs 2.52% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-11.20",
          "chgp": "32.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.90",
          "val2": "-11.60",
          "chgp": "31.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-137,948.30%",
          "val2": "-24,410.90%",
          "chgp": "-11,353.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-2.60
26.92%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.00
-2.70
25.93%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 25.93% vs -17.39% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.50
-80.00%
Operating Profit (PBDIT) excl Other Income
-7.60
-11.20
32.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.90
-11.60
31.90%
Operating Profit Margin (Excl OI)
-137,948.30%
-24,410.90%
-11,353.74%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -80.00% vs -64.29% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 31.90% vs 2.52% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About BioCardia, Inc. stock-summary
stock-summary
BioCardia, Inc.
Pharmaceuticals & Biotechnology
BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.
Company Coordinates stock-summary
Company Details
125 Shoreway Rd Ste B , SAN CARLOS CA : 94070-2718
stock-summary
Tel: 1 650 2260120
stock-summary
http://www.biocardia.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."